Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy
Latest Information Update: 08 Apr 2025
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms AERN
Most Recent Events
- 03 Apr 2025 Planned End Date changed from 1 Dec 2024 to 4 May 2025.
- 10 Dec 2024 Results evaluating Abscopal effect of radiotherapy and nivolumab in relapsed Hodgkin Lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition.
- 26 Jul 2024 Status changed from recruiting to active, no longer recruiting.